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ABSTRACT
COMBINING NOXA-INDUCING DRUGS WITH ABT-263 TO
EFFICIENTLY INCREASE CELL DEATH IN HEAD AND NECK
SQUAMOUS CELL CARCINOMA (HNSCC)
By: Sung Woo Kim, B.S.

A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2017

Major Director: Dr. Hisashi Harada, Ph. D
VCU School of Dentistry
Philips Institute for Oral Health Research

Head and neck cancer is the sixth leading cancer worldwide. Head and neck squamous
cell carcinoma (HNSCC) accounts for more than 90% of incident cases. Despite intense,
multimodality treatment regimens for HNSCC including surgery, chemotherapy, and
radiation, little progress has been made over the past 30 years in improving overall
survival rates. Tumor cell death induced by both conventional and targeted
chemotherapy is often mediated by the BCL-2 family-dependent mitochondrial apoptotic
pathway. However, initiators of this apoptotic pathway, such as p53, are more than 50%
of the time mutated or deleted in HNSCC rendering the disease refractory to treatment.
To counter such resistance, direct therapeutic targeting of the BCL-2 family is
ix

conceptually appealing. For this purpose, we use three clinically-available drugs:
cisplatin, fenretinide, and ABT-263 (navitoclax). Both cisplatin and fenretinide are
known to induce a BH3-only pro-apoptotic protein, Noxa, which binds to and inactivates
multi-domain anti-apoptotic protein MCL-1 and release from its interaction with multidomain pro-apoptotic protein BAK, followed by the phosphorylation via CDK2 for the
proteasome-mediated degradation. Activated BAK can now go through conformational
change for the oligomerization at the outer membrane of the mitochondria to release
cytochrome c into the cytosol and induce caspase-dependent apoptotic cell death. ABT263 directly binds to multi-domain anti-apoptotic proteins, such as BCL-2 and BCL-XL,
to inhibit their activity and leads to the activation of multi-domain pro-apoptotic protein
BAX to induce apoptosis.
We hypothesize that combining the Noxa-inducing drugs (cisplatin or fenretinide)
along with ABT-263 can efficiently induce BAX and BAK activation and significantly
increase cell death in HNSCC cells by simultaneously inhibiting the activity of MCL-1,
BCL-2, and BCL-XL. Combination-induced treatments in four cell lines (HN8, HN30,
HN31, and UMSCC1) tested led to significant increase in apoptotic cell death. Cisplatin
and ABT-263 combined treatment is inducing the expression of Noxa and leading to
increase in apoptosis in HN30, HN31, UMSCC1, but not HN8. Similarly, fenretinide and
ABT-263 combined treatment is inducing the expression of Noxa in all four cell lines
tested and is largely relying on expression of Noxa.

x

INTRODUCTION

1.1 Cancer
Cancer is a genetic disease that is caused by an uncontrolled division of abnormal
cells in a part of the body due to altering genes. Cancer has a major impact on society in the
United States and across the world. The statistics have estimated 1,685,210 new cases of
cancer to be diagnosed in 2016 in the United States and 595,690 will die from this leading
cause of death [www.cancer.gov]. Among various types of cancers, the deadliest types
include stomach, lung, liver, colorectal, breast, and esophageal cancer [www.who.org].
With this increasing number of deaths and new cases each year, it is extremely critical that
we understand and make significant progression in molecular mechanisms of tumorigenesis
and cell death.
While cancer can arise from genetic alterations, there are other factors that people
cannot control, such as age and family history. Other environmental risk factors also
include, but are not limited to tobacco, radiation, sunlight, and alcohol. Use of tobacco
products is the leading cause of cancer and of death from cancer because tobacco products
and secondhand smoke contain many chemicals that damage DNA. Tobacco use causes
many types of cancer, including cancer of the lung, larynx (voice box), mouth, esophagus,
throat, bladder, kidney, liver, stomach, pancreas, colon and rectum, and cervix, as well as
acute myeloid leukemia. People who use smokeless tobacco (snuff or chewing tobacco)
have increased risks of cancers of the mouth, esophagus, and pancreas [www.cancer.gov].
Radiation of certain wavelengths are also called ionizing radiation, which has enough
energy to damage DNA and cause cancer. High-energy radiation, such as x-rays, gamma
1

rays, alpha particles, beta particles, and neutrons can also damage DNA and cause cancer.
While these are some of the primary causes of cancer, there are many other risk factors of
developing cancer, such as obesity, human immunodeficiency virus (HIV), human
papillomavirus (HPV), hormones, infectious agents, and age [www.cancer.gov].

1.2 Head and neck cancer
Head and neck cancer is a general term used to describe a number of different
deadly tumors that arise from squamous cell lining the epithelium of the oral cavity, nasal
cavity, pharynx, larynx, paranasal sinuses, and salivary glands, hence called head and neck
squamous cell carcinoma (HNSCC) [1]. HNSCC is the sixth leading cancer worldwide.
Head and neck cancers account for approximately three percent of all cancers in the United
States, and these cancers are nearly twice as common among men as they are among
women [2,3]. Symptoms of head and neck cancers include a lump or a sore that does not heal
nor go away, difficulty in swallowing, and a change or hoarseness in the voice
[www.cancer.gov]. Individuals who are older than 50 are most vulnerable to HNSCC and
many of them have been exposed to one or more of the risk factors [www.cancer.gov]. The
survival rate for individuals diagnosed with head and neck cancer has not changed
significantly over the past 50 years and have been remaining at 50 percent
[www.mcancer.org].
Alcohol and tobacco are the two most important risk factors for head and neck
cancers, which accounts for at least 75 percent of all head and neck cancers [4]. These two
highest risk factors mainly affect the oral cavity, oropharynx, hypopharynx, and larynx [5].
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Alcohol and tobacco are not risk factors for salivary gland cancers. Another high-risk factor
for some types of head and neck cancers, particularly oropharyngeal cancers that involve
the tonsils or base of the tongue is human papillomavirus (HPV), especially HPV-16 [6-8]. In
the United States, the incidence of oropharyngeal cancers caused by HPV infection is
increasing, while the incidence of oropharyngeal cancers related to other causes is falling [6].
Treatment of the head and neck cancers may vary depending on its location and the
stage of cancer. Cancer staging is the process of finding out how much cancer is in a
person’s body and where it is located. For most types of cancer, doctors use staging
information to help plan treatment and to predict a patient’s prognosis [www.cancer.org].
Although each person’s situation is different, cancers with the same stage tend to have
similar outlooks and are often treated with the same way. In order to stage cancers, doctors
use TNM classification system as a tool to stage different types of cancer based on certain
standards, and place the tumor from stage zero to four. The TNM classification system
considers the size of tumor, possible spread to lymph nodes, and possible metastasis to
other parts of the body [www.cancer.org]. At stage 0, abnormal cells are present but have
not spread to nearby tissue. Also, called carcinoma in situ, or CIS. CIS is not cancer, but it
may become cancer. Stage I tumors are estimated to be 2 cm in diameter or smaller, and no
other cancer cells are present in surrounding tissues or distant structures. Stage II tumors
measure 2-4 cm in diameter, yet no cancer cells are present in surrounding tissues or distant
structures. Stage III tumors have grown even larger to 4 cm in diameter or greater. Stage IV
is further divided into three subtypes: A, B, and C. Stage IV-A means that the tumor is in
any size, but is not found in lymph nodes or other parts of the body. Stage IV-B tumors
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invade deeper tissues and have spread to lymph nodes, but not into distant areas. Stage IVC tumors have spread to lymph nodes as well as other distant parts of the body
[www.cancercenter.com].
As already mentioned, treatment options may vary depending on which stage the
tumor is in. For tumors that are in stage I-II, either radiation or surgery is needed. For
further progressed patients at stage III-IV, treatments may include surgery, chemotherapy,
and radiotherapy. Some of chemotherapeutic drugs that are used to treat head and neck
cancers include docetaxel, gemcitabine, fluorouracil, carboplatin, and cisplatin.

1.3 Cell Death
Three major types of cell death include apoptosis, necrosis, and autophagy.
Apoptosis is a type I programmed cell death that occurs in multicellular organisms as a
result of caspase activation. This leads to the morphological changes of cells and is
characterized by cell shrinkage, plasma membrane blebbing, nuclear fragmentation,
chromatin condensation, and chromosomal DNA fragmentation. Apoptosis in general, is a
highly regulated and controlled process which confers advantage during an organism’s life
cycle. For example, separation of humans’ fingers and toes is regulated by apoptosis during
the embryological development. Autophagy is another type of cell death that is caspaseindependent. It is an intracellular degradation system that delivers the cytoplasmic
constituents to the lysosome. The most typical trigger of autophagy is the nutrient
starvation. Necrosis results in the premature death of cells in living tissue. Necrosis is
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caused by external factors to the cell, such as infections, toxins, or trauma. Unlike apoptosis,
necrosis is almost always detrimental to an organism and can be even fatal.
In order for human body to maintain proper homeostasis, apoptosis is extremely
important and must be in absolute control to balance out the amount of cell proliferation to
avoid cancer development. Excessive apoptosis causes atrophy, whereas an insufficient
amount of apoptosis results in uncontrolled cell proliferation, such as cancer. Some factors
like Fas receptors and caspases promote apoptosis while some members of the BCL-2
family of proteins inhibit apoptosis.
Apoptosis can be divided into two main pathways: intrinsic and extrinsic pathways
[15]

. The intrinsic pathway is characterized by permeabilization of the mitochondria and

release of cytochrome c into the cytoplasm. Cytochrome c then forms a multi-protein
complex that is known as apoptosome and initiates activation of the caspase cascade
through caspase-9. This pathway is often triggered by harmful stimuli, such as
chemotherapeutic drugs. When cytochrome c is released from the mitochondria, it binds to
the apoptotic protease-activating-factor 1 (APAF-1) to form apoptosome. This complex
then binds and forms another complex with pro-caspase 9 and cleaves it to release its active
form. Fully activated caspase-9 then leads to the activation of caspase-3. The extrinsic
pathway is activated by extracellular ligands binding to cell-surface death receptors and
these ligands include tumor necrosis factor-α (TNF- α) and Fas ligand (CD95), which leads
to the formation of the death-inducing signaling complex (DISC). Stimulation of death
receptors of the tumor necrosis factor (TNF) receptor superfamily such as CD95 (APO1/Fas) or TNF-related apoptosis-inducing ligand (TRAIL) receptors results in activation of
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the initiator caspase-8, which can propagate the apoptosis signal by direct cleavage of
downstream effector caspases such as caspase-3 [16].

Figure 1: Simplified diagram of the intrinsic and extrinsic pathways of apoptosis [16].

6

1.4 BCL-2 family
The BCL-2 family proteins consist of a number of proteins that share the BCL-2
homology (BH) domains, and they play a significant role in the regulation of apoptosis, a
form of programmed cell death, through mitochondrial pathway. Proteins in this family
either promote or inhibit apoptosis by governing mitochondrial outer membrane
permeabilization (MOMP). The family is subdivided into three classifications based on its
functions and by which BH domain it consists. As of today, four groups of BH domain
have been identified and proteins belonging to this family contain either BH1, BH2, BH3,
or BH4 domain. The BCL-2 family consists of three different groups of proteins: multidomain pro-apoptotic, multi-domain anti-apoptotic, and finally, BH3-only pro-apoptotic
proteins. Multi-domain pro-apoptotic includes BAX and BAK, multi-domain anti-apoptotic
includes BCL-2, MCL-1, BCL-XL, BCL-W, and A1. BH3-only pro-apoptotic proteins
include BAD, BIM, BID, and Noxa.
Upon activation of BAX and BAK, which contain all four BH domains, they
eventually go through the conformational change and oligomerize, then cytochrome c is
released into the cytosol from the mitochondria to trigger apoptosis through caspasedependent event, so called MOMP. Multi-domain anti-apoptotic proteins act to inhibit the
function of pro-apoptotic proteins, such as BAX and BAK by the protein-protein
interaction and prevent MOMP or release of cytochrome c into the cytosol. BH3-only proapoptotic proteins share homology only with the BH3 domain and they tend to inactivate
the activity of the anti-apoptotic proteins, such as BCL-2, BCL-XL and MCL-1. To
inactivate the activity of these anti-apoptotic proteins, the BH3-only protein’s BH3
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amphipathic helix binds to the hydrophobic pocket of anti-apoptotic proteins (BCL-2,
BCL-XL, and MCL-1), which prevents these anti-apoptotic proteins from interacting with
BAX and BAK for the pore formation to release cytochrome c. Some of the proteins within
this group, such as BID and BIM, have a unique ability to directly activate BAX and BAK
to induce caspase-dependent apoptosis. Due to differences of BH3-only protein’s BH3
domains and the groove in which they bind to, some BH3-only proteins, such as Noxa is
very selective and has high affinity to MCL-1 (myeloid cell leukemia 1) over any other
anti-apoptotic proteins, such as BCL-XL and BCL-2.
Without an apoptotic stimulus or cells in a healthy state, BAX is located in the
cytosol and remain inhibited by variety of anti-apoptotic proteins. However, upon
activation through apoptotic stimulus, such as DNA damage, it gets conformational change
to expose mitochondrial targeting sequence, and is sequestered to the outer membrane of
the mitochondria. On the other hand, BAK is normally located at the outer membrane of the
mitochondria and remain inhibited by anti-apoptotic proteins, such as MCL-1 and BCL-XL.
The BH grooves exist in all anti-apoptotic BCL-2 proteins. This groove of anti-apoptotic
proteins prevents the formation of pore at the outer membrane of the mitochondria by
binding to the BH3 domain of BAX or BAK and interferes with their conformational
change for activation. There are differences in BH3-only protein’s BH3 domains and
grooves in which they bind to. For example, BIM and BID are capable of binding to all
anti-apoptotic proteins, whereas Noxa is extremely selective and has much higher affinity
to MCL-1 while has lower affinity to other anti-apoptotic proteins.
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Figure 2: The list of BCL-2 family proteins. All BCL-2 family proteins contain BH3
domain.

1.5 MCL-1 and Noxa
MCL-1 (myeloid cell leukemia 1) was first discovered in 1993 in the differentiating
myeloid leukemia cells [17]. This protein encoded by this gene belongs to the BCL-2 family
proteins. Its major role is regulation of apoptosis and cell survival in both normal and tumor
cells. This protein is composed of 350 amino acids in human and lacks in BH4 domain,
while BCL-2 and BCL-XL contain BH1, BH2, BH3, and BH4 domain. The predominant
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function of MCL-1 is to prevent apoptosis through its protein-protein interaction with
multi-domain pro-apoptotic proteins, such as BAK. In the C-terminal portion of MCL-1,
there is a transmembrane domain that functions to localize MCL-1 to the outer membrane
of mitochondria [18]. The N-terminus of MCL-1 is unique amongst the BCL-2 family, in
that it is rich in putative regulatory residues and motifs. These include the sites for
ubiquitination, cleavage, and phosphorylation, which influence the protein stability,
localization, dimerization, and function [19]. The PEST domains at the N-terminus of MCL1 contain phosphorylation sites for protein kinases, such as JNK (c-JUN N-terminal kinase),
ERK (extracellular signal-regulated kinase), GSK3 (glycogen synthase kinase 3), CDK1
(cyclin-dependent kinase 1), and CDK2 (cyclin-dependent kinase 2). For instance, when the
GSK3 pathway is activated by the decrease in activation of AKT, it leads to
phosphorylation of MCL-1 and ultimately degradation. In contrast to GSK3 pathway, ERKmediated pathway phosphorylation of MCL-1 stabilizes the MCL-1 protein by
phosphorylating at Thr 163 in the PEST region, stimulated by 12-O-tetradecanoylphorbol
acetic acid (TPA)-induced activation of extracellular signal-regulated kinase (ERK) [35].
When healthy cells undergo apoptotic events due to cytotoxic stimulus, MCL-1 is often
down-regulated as a result of caspase cleavage. These activated caspases have the ability to
cleave MCL-1 at the N-terminus that is within the PEST domain, and lead to its loss of
function as an anti-apoptotic protein to interact with BAK to prevent apoptosis. Overall,
MCL-1 can be either phosphorylated for the proteasome-mediated degradation or by
cleavage by caspase to affect its function.
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Noxa is one of the BH3-only pro-apoptotic proteins that is identified as a target
gene of p53 (REF). It was first identified in 2000 and is composed of 54 amino acids in
human. Under the cytotoxic stimulus, such as DNA damage, Noxa is up-regulated, binds to
one of the anti-apoptotic BCL-2 family proteins MCL-1 at the BH3 domain and recruits at
the membrane of the mitochondria from cytosol. Upon interaction between Noxa and
MCL-1, phosphorylation of MCL-1 occur at Ser64/Thr70 sites and get ubiquitinated for
subsequent proteasome-mediated degradation. This phosphorylation event is primarily
regulated by CDK2 (cyclin-dependent kinase 2) [20]. This up-regulation of Noxa can be
either p53-dependent and also p53-independent. For example, application of cisplatin to
cause DNA damage triggers p53 to induce Noxa expression, whereas mitogenic stimulation
to induce Noxa through PKC (protein kinase c) is independent of p53. Upon up-regulation
of Noxa and subsequent activation of BAK, BAK can now go through conformational
change and oligomerize to form a pore in the outer membrane of the mitochondria,
releasing cytochrome c into the cytosol for further caspase-9 activation.
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Figure 3: Induction of Noxa and its interaction with MCL-1 to release BAK from MCL-1
for oligomerization [21].

1.6 Cisplatin
Cisplatin is a chemotherapeutic drug that is widely used to treat many different
types of cancers including non-small cell lung cancer, bladder cancer, cervical
cancer, ovarian cancer, head and neck cancer, and testicular cancer. It is often used to treat
metastasized and advanced types of cancers that cannot be treated by other methods, such
as radiation or surgery. Cisplatin works by interfering with the process of cell division,
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inducing cancer cell death and slowing or stopping the spread of cancer. The history of
cisplatin starts in 1844 when it was first created by Italian chemist Michele Peyrone. For a
long time, it was known as Peyrone’s chloride. In the mid-1900s, a biophysical chemist
Barnett Rosenberg and his colleagues have demonstrated cisplatin’s ability to inhibit cell
division and reduce the size of solid tumors [9,10]. Despite its wide use to treat many
different types of cancers, its complete mechanism as to how cisplatin induces cell death is
not fully understood.
Cisplatin (cis-PtCl2(NH3)2) consists of 11 atoms with platinum in the center
(Figure 1) [11]. What we do know is that cisplatin works by nucleophilic substitution
reaction. When cisplatin is intravenously injected, the chlorine atom gets replaced by a
hydroxyl group and binds covalently to DNA in the cell (Figure 2) [12]. The platinum in the
center is the key player to induce cell death in cancer cells, because this atom covalently
binds to adjacent N-7 guanine to form 1,2 intrastrand crosslinks [13,14]. This crosslinking
interaction results in many cellular responses including transcription inhibition, cell-cycle
arrest, DNA repair and apoptosis (Figure 2) [12]. The most common form of death induced
by cisplatin is through the BCL-2 family proteins to lead into apoptosis.
As a DNA damaging agent, cisplatin is often employed for the treatment of many
different types of tumors, including HNSCC. However, its prolonged use often leads to the
development of resistance [20]. It has been shown that a pro-apoptotic BH3-only protein,
Noxa is transcriptionally induced by cisplatin. When Noxa is induced, it binds to and
recruit MCL-1 at the outer membrane of the mitochondria, and release MCL-1 from its
interaction with BAK and/or BAX. Recruited MCL-1 is subsequently phosphorylated at
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Ser64/Thr70 by the formation of a complex with CDK2, leading to its proteasomemediated degradation [20]. When BAK/MCL-1 interaction is released, activated BAK can
now go through conformational change and oligomerize to form a pore at the outer
membrane of the mitochondria, releasing cytochrome c into the cytosol for further caspase9 activation.

http://www.scbt.com/datasheet-200896-cisplatin.html

Figure 4: The structural formula for cisplatin. The chemical name for cisplatin is cisdiamminedichloridoplatinum(II)
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Figure 5: Molecular interaction of cisplatin. Cisplatin’s cross-linking with DNA to inhibit
replication and induce cell death [12].

1.7 Fenretinide
Fenretinide (N-4-hydroxyphenyl-retinamide, or 4-HPR) is a semisynthetic retinoid
(Vitamin A) that was initially developed as a low-dose chemopreventative agent
[www.cancernetwork.com]. It has a vitamin A activity and is well-known for its anti-tumor
and differentiation-inducing activity in vitro and in vivo. While the mechanism of action of
fenretinide-induced apoptosis is not fully understood, it has been reported that fenretinide
binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation
and apoptosis in some tumor cell types. This agent also inhibits tumor growth by
modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid
receptor-independent apoptotic properties [www.cancer.gov]. Studies have shown that in
certain tumor types, such as neuroblastoma and melanoma, fenretinide induces apoptosis
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through endoplasmic reticulum (ER) stress, which is mediated by the eukaryotic initiation
factor 2alpha (eIF2alpha)-ATF4 signaling pathway [23]. Increased expression of eIF2alpha
and ATF4 correlated with induction of the BH3-only pro-apoptotic protein Noxa, followed
by inhibition of multi-domain anti-apoptotic protein MCL-1.
HNSCC has a high incidence of recurrence and associated second primary
malignancy. Fenretinide has been shown to be effective as both a chemopreventive and
chemotherapeutic agent for HNSCC, but often with treatment-limiting toxicity. Fenretinide
has significant anti-proliferative activity against a number of animal and human
malignancies and has been used in clinical trials as a chemopreventive agent in patients
with breast and prostate cancer and oral leukoplakia [24]. Through many research
experiments, fenretinide has been shown promise for treating many different types of
tumors, including HNSCC. The ability of fenretinide to enhance production of reactive
oxygen species (ROS) leading to apoptosis has been suggested as a possible mechanism

[29]

Rac was activated in human HNSCC cells as early as five minutes following fenretinide
exposure. Moreover, inhibition of Rac activity or silencing of its expression by RNA
interference decreased the ROS generation in human head and neck, lung, and cervical
cancer cells [29]. ROS is also known to be able to induce an ER stress response, which can
contribute to apoptosis, but may also antagonize it [30]. It has been reported that
combination of ABT-737, an inhibitor of BCL-XL, BCL-2, and BCL-W, and fenretinide
have synergistically decreased cell viability and caused death in multiple melanoma cell
lines, but not in normal melanocytes [25]. The combination of ABT-737 and fenretinide have
increased the Noxa expression and caspase-dependent MCL-1 degradation [25].
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Figure 6: ER-stress mediated cell death. ER stress leads to apoptotic cell death at
transcriptional, post-transcriptional, translational, and post-translational levels. Proapoptotic proteins, such as Noxa is induced as a result.

https://pubchem.ncbi.nlm.nih.gov/compound/fenretinide#section=Top
Figure 7: Structural formula of fenretinide.
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1.8 ABT-263 (navitoclax)
The BCL-2 family comprised of two broad categories of pro-survival (BCL-2,
BCL-XL, BCL-W, MCL-1, and A1) and pro-apoptotic (Noxa, BAX, BAK, BID, BIM, and
BAD) proteins [27]. The balance between these proteins determines whether a cell lives or
dies. The overexpression of pro-survival BCL-2 family members provides a mean by which
cancer cells can overcome the continual assault of cellular stresses that would cause normal
cells to undergo apoptosis. Their overexpression has also been shown to correlate with poor
prognosis and resistance to therapy [27]. For example, overexpression of BCL-2 has been
shown to confer resistance to cytotoxic agents in lung cancer, whereas both BCL-2 and
BCL-XL are associated with the emergence of androgen independence and chemoresistance
in prostate cancer [27].
ABT-263, also known as navitoclax, is an orally bioavailable, synthetic smallmolecule antagonist of a subset of the BCL-2 family of proteins with potential
antineoplastic activity [26]. It selectively binds to anti-apoptotic proteins BCL-2, BCL-XL,
and BCL-W, and prevents their binding to the apoptotic effectors BAX and BAK proteins,
which triggers apoptosis in tumor cells overexpressing BCL-2, BCL-XL, and BCL-W. In
human tumor cells, ABT-263 is known to induce BAX translocation, releasing cytochrome
c into the cytosol from the mitochondria, and subsequent caspase-dependent apoptosis.
While ABT-263 exhibits single-agent activity in tumors dependent on BCL-2 and BCL-XL
for survival, the expression of MCL-1, the main contributor to the caspase-dependent
apoptotic pathway has been shown to confer resistance to ABT-263. Furthermore, in some
xenograft models of aggressive lymphoma and in phase I/II clinical studies in patients of
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lung cancer, single-agent ABT-263 just exhibited modest or limited efficacy, with dosedependent thrombocytopenia induced by targeting BCL-XL in megakaryocytes [28]. To
solve this limitation, recent studies are more focusing on combining the ABT-263 with
other chemotherapeutic drugs. For this reason, we can not only minimize the side effects by
combining ABT-263 along with Noxa-inducers (cisplatin or fenretinide), but also to
simultaneously block multi-domain anti-apoptotic proteins (BCL-2, BCL-XL, and MCL-1)
to efficiently increase the amount of apoptosis in HNSCC.

Figure 8: Translocation of BAX to the outer membrane of mitochondria. BAX
translocation leads to release of cytochrome c into the cytosol for caspase-dependent
apoptotic cell death.
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https://pubchem.ncbi.nlm.nih.gov/compound/Navitoclax#section=Top
Figure 9: Structural formula of ABT-263.

1.9 p53
p53 was first identified in 1979 by Arnold Levine, David Lane, and William Old.
Although it was first presumed to be an oncogene, its character as a tumor suppressor gene
was revealed in 1989 [www.bioinformatics.org]. It is very important for cells in
multicellular organisms to suppress cancer. p53 has been described as "the guardian of the
genome", referring to its role in encoding for proteins that regulate the cell cycle and hence
functions as a tumor suppressor. Defective p53 can allow abnormal cells to proliferate,
resulting in cancer. As many as 50% of all human tumors contain p53 mutants. p53 is often
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activated by stresses, such as ultraviolet, x-rays, chemotherapeutic drugs, and DNA
synthesis inhibitors. Kinases, such as Chk1, Chk2, and ATM phosphorylate p53 protein to
prevent from degradation. High concentration of p53 stops the cell cycle at G1/S and
induces DNA repair proteins to fix the damage and prevent replication of the damaged
DNA. When DNA damage is repaired, phosphorylation by kinases that protect the p53
degradation disappear and the cell cycle resumes its activity to replicate the DNA in the S
phase. If DNA damage cannot be repaired, p53 acts as a transcription factor to induce the
expressions of several pro-apoptotic target genes, such as Noxa and Puma for the apoptotic
cell death. The cellular concentration of p53 must be tightly regulated. In normal cells, p53
protein level is low and this is because p53 is constantly being degraded by the major
regulator protein called MDM2 (in human). This protein binds to the N-terminus of p53
and triggers polyubiquitylation and proteasome-mediated destruction.
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HYPOTHESIS
Cisplatin induces anti-cancer effects through the induction of BCL-2 familydependent mitochondrial apoptosis. One of the BCL-2 family proteins that are induced is
Noxa. This protein selectively binds to anti-apoptotic MCL-1 to inactivate its function and
release BAK to cause apoptosis. Similarly, fenretinide has been shown to induce Noxa
through ER stress and inactivate the function of anti-apoptotic protein MCL-1. On the other
hand, ABT-263 selectively and directly binds to the apoptosis suppressor proteins, such as
BCL-2 and BCL-XL, but not MCL-1. This direct binding prevents anti-apoptotic proteins
from binding to the multi-domain pro-apoptotic proteins BAK and/or BAX. We
hypothesize that combining the Noxa-inducing drugs (cisplatin or fenretinide) with
ABT-263 can efficiently induce BAX and/or BAK activation and significantly increase
cell death in HNSCC cells by simultaneously inhibiting the activity of MCL-1, BCL-2,
and BCL-XL.
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SPECIFIC AIMS

3.1 Determine how much apoptosis can increase in HNSCC cells by treating with both
cisplatin or fenretinide along with ABT-263, compared to single treatments.
The toxicity level of cisplatin, fenretinide, ABT-263, and combination was measured. Cell
death was determined by Western blot analyses and Annexin V-propidium iodide (PI)
staining, followed by FACS analyses.

3.2 Determine the molecular mechanisms of Noxa-induced cell death in HNSCC cells.
The lentiviral short-hairpin Noxa (shNoxa) expressing constructs were introduced to
HNSCC cells to infect and knock-down the expression of the Noxa to determine the
involvement of Noxa in cisplatin, feretinide, ABT-263, and combination-induced cell death.
The cell death will be determined by Western blot analyses and Annexin V-PI staining,
followed by FACS analyses.
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MATERIALS AND METHODS

4.1 Cell lines and cell culture
HN12, HN22, HN8, HN30, and HN31 head and neck squamous cell carcinoma (HNSCC)
cells were provided by Dr. Andrew Yeudall (Augusta University, GA), UMSCC1 cells
were provided by Dr. Yue Sun (Virginia Commonwealth University). All cell lines were
cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies) with
addition of 10% heat-inactivated fetal bovine serum (FBS) (Gemini Bio-Products, West
Sacramento, CA) and 5% 100 μg/mL penicillin G/streptomycin (Invitrogen) at 37°C in a
humidified, 5% CO2 incubator. 293T cells were purchased from the American Type
Culture Collection (Manassas, VA). HN30/sh-Noxa, HN30 shC, UMSCC1/sh-Noxa, and
UMSCC1 shC cells were maintained with 2 μg/mL of puromycin (InvivoGen, San Diego,
CA) for selection.

4.2 Plasmid transfection and lentivirus infection
The lentiviral short-hairpin RNA (shRNA) expressing constructs were purchased from
Open Biosystems (Huntsville, AL) or Sigma-Aldrich (St. Louis, MO). The constructs were
transfected into 293T packaging cells along with the packaging plasmid (Addgene;
Cambridge, MA) and lentivirus-containing supernatants were collected. A cell line of
interest was seeded in a 6-well plate and the plate containing the media (DMEM) was
removed on the following day. Subsequently, 1 mL of DMEM and 1 mL of collected
supernatant containing the lentiviruses were added, and further treated with 2 μL of
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polyburene. It was then spun down at 2000 rpm for 1 hour in the centrifuge to facilitate the
binding process of viruses to the cells.

4.3 Chemicals and antibodies
Cisplatin (sc-200896) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibodies for BIM, Cleaved PARP (Asp214), GAPDH (D16H11), Cleaved Caspase -3
(Asp175), HRP-linked anti-mouse IgG, and HRP-linked anti-rabbit IgG were from Cell
Signaling Technology (Beverly, MA); MCL-1 (ADI-AAP-240-F) from Enzo Life Sciences
(Farmingdale, NY); p53 (sc-126) from Santa Cruz Biotechnology (Santa Cruz, CA); Noxa
(114C307.1) from Thermo Fisher Scientific (Waltham, MA); ECL 2 Western blotting
substrate (80196) was purchased from Thermo Scientific (Rockford, IL). Annexin V-FITC
was purchased from BD Biosciences (California, USA), and propidium-iodide from Sigma
Aldrich Inc. (St. Louis, MO).

4.4 Western blot
To perform Western blots, whole HNSCC cell lysates were prepared with CHAPS
lysis buffer [20 mM Tris (pH 7.4), 137 mM NaCl, 1 mM dithiothreitol (DTT), 1% CHAPS
(3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate), 1:200 ratio of protease
inhibitor cocktail (Sigma Aldrich), and 1:100 ratio of phosphatase inhibitor cocktails 2 and
3 (Sigma)]. Protein concentrations from the lysates were measured by spectrophotometric
analysis with the Bradford method (Bio-rad, Hercules, CA), and equal amounts of samples
were loaded into SDS-polyacrylamide gels. The gel was electrophoresed at 180 volts for
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approximately 45 minutes and the proteins were transferred onto a nitrocellulose membrane
(Fischer Scientific, Pittsburgh, PA) with 100 volts for one hour. The nitrocellulose
membrane was then blocked with a blotting solution [5% skim milk in PBST (1 x PBS with
0.1% Tween-20)] for 20 minutes, and specific primary antibodies were incubated with the
membrane for overnight at 4°C. The incubated membrane was washed with PBST for at
least five minutes for three times and then either HRP-linked anti-mouse IgG or anti-rabbit
IgG antibodies were incubated with the membranes for one hour at room temperature. The
membranes were washed three times with PBST for five minutes. The membrane was then
developed using Pierce ECL- 2 Western Blotting Substrate (Thermo Fisher Scientific).

4.5 FACS analysis
To perform fluorescence-activated cell sorting (FACS) analysis, cell lines of interest
were seeded in a 12-well plates and treated with cisplatin (20 μM), fenretinide (10 μM),
ABT-263 (1 μM), and combined drugs. Cells were harvested at 24 or 48-hour time points
and was spun down in the centrifuge for one minute at 7000 rpm. Then, the cell pellets in
each tube were suspended in 1 ml of cold 1x PBS. PBS-washed cells were then spun again
in the centrifuge for one minute at 7000 rpm, followed by aspiration of the supernatant.
Then, 100 μL of binding buffer was added into each tube and transferred to a 5 ml
polystylene tube. Total 13 μL of Annexin V (3 μL)-propidium iodide (10 μL) was added
into each tube, and was left in the dark for 15 minutes to avoid bleaching dyes. Finally,
additional 400 μL of binding buffer was added into each tube and was analyzed through the
FACS Caliber (BD Biosciences).

26

4.6 Cell toxicity (WST-1) assay
HNSCC cells were seeded in triplicate in microtiter plates (96 wells) with 1x104 cells per
well in 150 μL medium. On the following day, cells were treated with different
concentration of cisplatin and 48 hours later, 2 μL of WST-1 reagent was added to the cells.
The WST-1 assay is based on tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-(4nitrophenyl)-2H-5-tetrazolio]-1, 3- benzene disulphonate). It is used to determine the
cytotoxicity of cisplatin by measuring the absorbance of the samples with a microplate
enzyme-linked immunosorbent assay (ELISA) reader (Promega Life Sciences).

4.7 IC50
IC50 (half maximal inhibitory concentration) is a term that represents an amount of specific
substance (inhibitor) needed to inhibit 50 percent of cell’s biological or biochemical
mechanisms, i.e. an enzyme, receptors or microorganism. IC50 for cisplatin cytotoxicity
was calculated for each HNSCC cell line by obtaining quantitative measurements from the
microplate ELISA 450nm reader. The measurements were entered in Excel sheets to
calculate the IC50.

4.8 Statistics
The mean, or average, represented by bar graphs is calculated by finding the sum of the
study data and dividing it by the total number of data. Error bars indicated by a line through
the graph represent the error of the corresponding study (Mean ± S.D.). The standard
deviation (S.D.) is used to quantify the amount of variation of a set of data values. Errors
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were calculated by taking the difference between the largest and smallest values of our
collected data. P-values were also calculated through t-test in order to quantify the idea of
statistical significance of our evidence. P-values < 0.05 suggest that our results are
statistically significant.
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RESULTS
5.1 HNSCC cell lines and their cisplatin sensitivity, IC50
Table 1 contains the list of head and neck squamous cell carcinoma cell lines that
were used in this study and their primary origin as well as main characteristics [34]. Cell
lines that are harvested from the lymph node are post-metastatic. The p53 gene in HN8 is
deleted, HN30 and UMSCC1 harbors the wild-type p53, and HN31 harbors a mutation
within the p53 gene, but the gene still retains some function [20,31,32].

TABLE 1. HNSCC Cell Lines

Patient

Cell Line

Origin

p53 Status

IC50 (μM)
Cisplatin

A

HN8

Lymph node

Deleted

50

HN30

Pharynx

Wild-type

21

HN31

Lymph node

Mutated

20

UMSCC1

Floor of mouth

Wild-type

15

B

C

IC50 of the cell lines were determined by the WST-1 (tetrazolium salt) assay. When
cells are metabolically active, WST-1 is cleaved to form a soluble formazan dye, which can
be quantified by a scanning multi-well spectrophotometer at 450 nm (Figure 8) [33].
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Figure 10: Cleavage of WST-1 (tetrazolium salt) to formazan. (EC: electron coupling
reagent, RS: mitochondrial succinate-tetrazolium-reductase system)[33].

We found that p53 wild-type cell UMSCC1 had the lowest IC50 of 15 µM, while
p53-deleted HN8 had the highest IC50 of 50 µM. HN30 that has wild-type p53 and HN31
with mutant p53 had IC50 of 21 µM and 20 µM, respectively.
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A)

B)
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C)

D)

Figure 11 (A-D): IC50 of cisplatin treatment in HNSCC cell lines. HNSCC cell lines
were treated with various concentrations of cisplatin for 48 hours. Percentage of survival
was determined by the WST-1 assay [34].
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5.2 Noxa-inducers combined with ABT-263 show dramatic increase in apoptotic cell
death in HNSCC cells.
To examine whether combination-induced apoptotic cell death is dramatically
increased in HN8, HN30, HN31, and UMSCC1, each cell line was seeded in 6-well plates
and treated with DMSO for control, cisplatin (20 μM), fenretinide (10 μM), ABT-263 (1
μM), cisplatin with ABT-263, and fenretinide with ABT-263. Cells were harvested at 16hour time point and probed with cleaved-PARP, MCL-1, BIM, and Noxa. PARP is a
substrate that is cleaved off when caspase-3 is activated during caspase-dependent
apoptosis, and therefore is a strong indication of apoptotic event.
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HN8 cell line has a noticeable increase in cleaved-PARP when treated with
fenretinide and ABT-263 together compared to each treatment alone, indicating the
synergistic cell death activity with these two chemotherapeutic drugs. The expression level
of Noxa is also consistent with the amount of cleaved-PARP, suggesting that fenretinide or
fenretinide with ABT-263-induced apoptotic cell death is largely depending on Noxa.
However, the effect of cisplatin with ABT-263-induced apoptotic cell death seems additive
as combination-induced cell death is not significantly increased compared to single
treatment. Our result observed in Western blot analysis is also consistent with the cell
death observed through FACS analysis.

Figure 12: HN8 is noticeably responsive to fenretinide + ABT-263 combination
treatment. Left) HN8 cells were treated with indicated drugs for 16 hours and equal
amounts of samples were analyzed by Western blots using indicated antibodies. GAPDH
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was used to confirm the equal loading of total lysates. Right) HN8 cells were treated with
indicated drugs for 24 hours and fluorescent-activated cell sorting (FACS) analysis was
performed to determine the total amount of apoptosis (N = 4). Error bars that represent the
standard deviation is depicted by a line through the bar graphs showing the amount of
variation of a set of data values.

HN30 is one of the cell lines we observed the most synergistic increase of apoptotic
cell death. We observed a significant increase in cleaved-PARP as a result of combinationinduced cell death, both in CA (cisplatin + ABT-263) and FA (fenretinide + ABT-263).
The expression level of Noxa has noticeably increased in combined treatment, which wellcorrelated with the cleaved-PARP. MCL-1 is also greatly reduced as a result of induction of
Noxa under fenretinide + ABT-263-induced apoptosis.

Figure 13: HN30 is largely responsive to both types of combination-induced apoptosis.
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Left) HN30 HNSCC cells were treated with indicated drugs for 16 hours and equal
amounts of samples were analyzed by Western blots using indicated antibodies. GAPDH
was used to confirm the equal loading of total lysates. Right) HN30 cells were treated with
indicated drugs for 24 hours and fluorescent-activated cell sorting (FACS) analysis was
performed to determine the total amount of apoptosis (N = 4). Error bars that represent the
standard deviation is depicted by a line through the bar graphs showing the amount of
variation of a set of data values.

The HN31 cell line is established from the same patient, although p53 is mutated.
However, this cell line was more responsive to cisplatin + ABT-263-induced treatment.
The level of MCL-1 is inversely correlated with the expression level of Noxa. Cisplatin and
ABT-263 together resulted in most apoptosis, which was indicated by cleaved-PARP.
Single treatment of cisplatin seems more effective in inducing apoptosis than fenretinide +
ABT-263 combined treatment. Our result from the Western blot analysis is also confirmed
through FACS analysis and the amount of total apoptosis is also well-correlated.
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Figure 14: Combination-induced cell death has significantly increased apoptosis.
Left) HN31 HNSCC cells were treated with indicated drugs for 16 hours and equal
amounts of samples were analyzed by Western blots using indicated antibodies. GAPDH
was used to confirm the equal loading of total lysates. Right) HN31 cells were treated with
indicated drugs for 24 hours and fluorescent-activated cell sorting (FACS) analysis was
performed to determine the total amount of apoptosis (N = 4). Error bars that represent the
standard deviation is depicted by a line through the bar graphs showing the amount of
variation of a set of data values.
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UMSCC1 also showed similar response as HN31 in terms of cleaved-PARP. It is
well-responded to cisplatin + ABT-263 combination treatment. Cisplatin + ABT-263
combination results in the most apoptosis, followed by cisplatin alone, and fenretinide +
ABT-263 combined treatment. The expression of Noxa is strongly induced by combined
treatments, but also by cisplatin alone. We also observed that BIM, another BH3-only proapoptotic protein, has greatly reduced by combination-induced cell death. Our result from
the Western analysis is further confirmed through FACS analysis.

Figure 15: Cisplatin + ABT-263-induced treatment significantly increased the
apoptotic cell death.
Left) UMSCC1 cells were treated with indicated drugs for 16 hours and equal amounts of
samples were analyzed by Western blots using indicated antibodies. GAPDH was used to
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confirm the equal loading of total lysates. Right) UMSCC1 cells were treated with
indicated drugs for 24 hours and fluorescent-activated cell sorting (FACS) analysis was
performed to determine the total amount of apoptosis (N = 4). Error bars that represent the
standard deviation is depicted by a line through the bar graphs showing the amount of
variation of a set of data values.

5.3 The contribution of Noxa in combination-induced cell death.
To examine if combination treatment induces Noxa to cause cell death, we
introduced short-hairpin RNA (shRNA) for Noxa to downregulate its expression. As
control, we introduced non-targeting shRNA. Both sh-control and sh-Noxa expressing
HNSCC cells were treated similarly as the previous experiments.
As shown in Figure 16 and 17, a clear reduction of apoptosis with down-regulation
of Noxa was observed in cisplatin + ABT-263 and fenretinide + ABT-263. This reduction
suggests that Noxa is contributing to apoptosis in these treatments. Knock-down of Noxa
expression is also leading to greater amount of MCL-1. UMSCC1 in Figure 18 also shows
a clear reduction in cleaved-PARP with decreased expression of Noxa. Both combined and
single treatments are largely depending on the expression of Noxa, however, single
cisplatin treatment is not affected by downregulation of Noxa, suggesting that its cell death
is depending on other BH3-only pro-apoptotic proteins. Our result from the Western
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analysis is further confirmed through FACS analysis, and the total amount of apoptosis was
consistent.

Puma is another p53 target gene. We decided to examine whether BH3-only protein
Puma is contributing to apoptosis. We observed that Puma is strongly induced under the
cisplatin single treatment, whereas in cisplatin and ABT-263 combined treatment, Noxa is
largely induced.

Figure 16: Noxa plays a critical role in the induction of apoptotic cell death in
combined treatments in HN30. The lentiviruses encoding short-hairpin Noxa (shNoxa) or
scrambled control (shC) were infected to HN30. Then the cells were treated with indicated
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drugs for 16 hours and equal amounts of samples were analyzed by Western blots using
indicated antibodies.

Figure 17: Combination-induced apoptotic cell death in HN30 is depending on the
expression of Noxa. The lentiviruses encoding short-hairpin Noxa (shNoxa) or scrambled
control (shC) were infected to HN30. Then cells were treated with indicated drugs for 24
hours and fluorescent-activated cell sorting (FACS) analysis was performed to determine
the total amount of apoptosis (N = 4). Error bars that represent the standard deviation is
depicted by a line through the bar graphs showing the amount of variation of a set of data
values.
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Figure 18: Noxa plays a partial role in induction of apoptotic cell death in fenretinide
+ ABT-263 combination treatment. The lentiviruses encoding short-hairpin Noxa
(shNoxa) or scrambled control (shC) were infected to UMSCC1. Then the cells were
treated with indicated drugs for 16 hours and equal amounts of samples were analyzed by
Western blots using indicated antibodies.
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Figure 19: Fenretinide + ABT-263-induced apoptotic cell death in UMSCC1 is
depending on the expression of Noxa. The lentiviruses encoding short-hairpin Noxa
(shNoxa) or scrambled control (shC) were infected to UMSCC1. Then cells were treated
with indicated drugs for 24 hours and fluorescent-activated cell sorting (FACS) analysis
was performed to determine the total amount of apoptosis (N = 4). Error bars that represent
the standard deviation is depicted by a line through the bar graphs showing the amount of
variation of a set of data values.
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5.4 The contribution of p53 in combination-induced cell death.
Cisplatin treatment of HNSCC cells results in DNA damage, which then activates
p53 to prevent the replication of damaged DNA. If this damage is irreparable, p53 will act
as a transcription factor to induce the expressions of several pro-apoptotic target genes. One
of these proteins induced by activation of p53 is BH3-only pro-apoptotic protein Noxa. To
examine whether p53 induces the expression of Noxa in combination treatments and further
lead to apoptotic cell death, we introduced short-hairpin RNA (shRNA) for p53 to
downregulate its expression. As control, we introduced non-targeting shRNA. Both shcontrol and sh-p53 expressing HNSCC cells were treated similarly as the previous
experiments. Figure 20 shows a clear reduction in cleaved-PARP in cisplatin-induced and
ABT-263-induced cell death with decreased expression of p53. The expression levels of
Noxa and p53 also correlates. However, we observed that decreased expression of p53 has
no effect on cleaved-PARP under the fenretinide + ABT-263 (FA) treatment. On the other
hand, FA combination-induced apoptotic cell death in UMSCC1 (Figure 21) was shown
under the FACS analysis when p53 is down-regulated.
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Figure 20: p53 is involved in fenretinide + ABT-263-induced cell death. The
lentiviruses encoding short-hairpin p53 (shp53) or scrambled control (shC) were infected to
HN30. Then the cells were treated with indicated drugs for 16 hours and Western blot
analysis was performed with the indicated antibodies to determine its effect on cell death.
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Figure 21: p53 is contributing to fenretinide + ABT-263 combination cell death. The
lentiviruses encoding short-hairpin p53 (shp53) or scrambled control (shC) were infected to
HN30. Then cells were treated with indicated drugs for 24 hours and fluorescent-activated
cell sorting (FACS) analysis was performed to determine the total amount of apoptosis (N
= 4). Error bars that represent the standard deviation is depicted by a line through the bar
graphs showing the amount of variation of a set of data values.
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5.5 Contribution of BIM in combination-induced cell death
BIM is known as BH3-only pro-apoptotic protein that cause the release of
cytochrome c from the mitochondria by activating BAX and/or BAK. To examine if BIM is
contributing to apoptosis in combination treatments, we introduced short-hairpin RNA
(shRNA) for BIM to downregulate its expression. As control, we introduced non-targeting
shRNA. Both sh-control and sh-Bim expressing HNSCC cells were treated similarly as the
previous experiments. Our result in Figure 22 clearly shows a reduction in the expression
level of BIM, indicating that our shBim construct is working well. However, in both
cisplatin + ABT-263 and fenretinide + ABT-263 treatments, the expression of cleavedPARP has not much changed when BIM was knocked down, suggesting that BIM is not
contributing to apoptosis.
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Figure 22: BIM is not involved in combination-induced cell death. The lentiviruses
encoding short-hairpin Bim (shBim) or scrambled control (shC) were infected to UMSCC1.
Then the cells were treated with indicated drugs for 16 hours and Western blot analysis was
performed with the indicated antibodies to determine its effect on cell death.

Figure 23: BIM is not contributing to the cell death in combination treatments. The
lentiviruses encoding short-hairpin Bim (shBim) or scrambled control (shC) were infected
to UMSCC1. Then cells were treated with indicated drugs for 24 hours and fluorescentactivated cell sorting (FACS) analysis was performed to determine the total amount of
apoptosis (N = 4). Error bars that represent the standard deviation is depicted by a line
through the bar graphs showing the amount of variation of a set of data values.
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DISCUSSION

6.1 The sensitivity of cisplatin relatively correlates with the status of p53 in HNSCC cell
lines
Treating HNSCC cells with cisplatin results in DNA damage, inducing p53 to
prevent DNA replication or induce apoptosis when DNA cannot be repaired. While
determining the IC50 of the HNSCC cell lines tested, we observed that cell lines with wildtype p53 had higher sensitivity to cisplatin than the cell lines with p53 deletion or nonfunctional p53 (Table 1 and Figure 11). This results suggest that cisplatin treatment largely
induces p53-dependent pathway to induce apoptosis.

6.2 Cleaved-PARP was increased in combination-induced cell death
In HN8 cell line, we observed that cisplatin + ABT-263 combination treatment was
not synergistic in inducing apoptosis, whereas fenretinide + ABT-263 treatment resulted in
significant increase in cleaved-PARP (Figure 12). Our results from the Western blot
analysis further confirmed through the FACS analysis. In cisplatin + ABT-263 treatment, it
is known that the activation of p53 induces the expression of Noxa to cause cell death.
Whereas in fenretinide + ABT-263, it is known that ER stress activates the transcription
factor ATF4 to induce Noxa for apoptosis. Since HN8 does not possess p53 to begin with,
it would not be as efficient to induce the pro-apoptotic Noxa to cause cell death by cisplatin.
Unlike cisplatin + ABT-263 treatment, fenretinide + ABT-263 treatment was still capable
of inducing Noxa to cause significant amount of cell death because induction of Noxa does
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not depend on the p53 status (Figure 12). In contrast, both HN30 and UMSCC1 cell lines
that harbor wild-type p53, and HN31 that has mutated p53 seemed to have very high
sensitivity to the cisplatin. Both cisplatin + ABT-263 and fenretinide + ABT-263 treatments
in HN30, HN31, and UMSCC1 have significantly increased the amount of apoptotic cell
death with increased expression of Noxa.

6.3 Knock-down of Noxa decreased cleaved-PARP expression in combination treatments
A BH3-only pro-apoptotic protein Noxa is known to sequester anti-apoptotic
protein MCL-1 and lead to apoptotic cell death. We observed in HN30 cell line that there
was decrease in cleaved-PARP when Noxa was knocked down in both combination
treatments (Figure 16). This suggests that combination-induced Noxa expression is
required to induce apoptosis. Although both CA (cisplatin + ABT-263) and FA (fenretinide
+ ABT-263) treatments are largely depending on the expression of Noxa, CA treatment in
shNoxa did not result in as much reduction in cleaved-PARP as FA treatment. These results
were further confirmed through FACS analysis (Figure 16 and 17). Thus, we investigated
whether CA treatment may be inducing other pro-apoptotic proteins, such as Puma. We
have observed clear induction of Puma in both cisplatin alone or CA treatment (Figure 16).
We speculate that Puma can also be contributing to apoptosis in these treatments and is
why down-regulation of Noxa is not resulting in as significant decrease in cleaved-PARP
compared to the FA treatment. We have also tested identical treatments in UMSCC1 cell
line with shNoxa. We have observed similar results that FA might be depending more on
Noxa, whereas CA is partially depending on the expression of Puma to induce apoptosis
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(Figure 18).

6.4 Contribution of p53 in combination-induced cell death
p53 is known as a transcription factor that induces the expressions of several proapoptotic proteins, such as Noxa and Puma. We wanted to investigate whether p53 is
contributing in apoptosis in p53 wild-type HN30 and UMSCC1 cell lines. As previously
discussed in 6.2, induction of Noxa in FA (fenretinide + ABT-263) treatment would depend
on ER stress, whereas induction of Noxa in CA (cisplatin + ABT-263) treatment would
depend on activation of p53. We have observed in HN30 that FA treatment was not
affected in the amount of cleaved-PARP when p53 was down-regulated. However, CA
treatment which is known to depend on p53 seemed to have slight reduction in cleavedPARP when p53 was knocked down (Figure 20). These results further confirm that CA
treatment leads to activation of p53 to induce Noxa to cause apoptosis, whereas FA
treatment leads to ER stress to induce Noxa to cause apoptosis.

6.5 Contribution of BIM in combination-induced cell death
BIM is known as BH3-only pro-apoptotic protein that causes the release of
cytochrome c to induce apoptosis by activating BAX and/or BAK. Throughout our
experiments here, we have seen the expression levels of BIM under combination treatments
were substantially decreased in combination treatments. Therefore, we further investigated
whether BIM was contributing to cell death with combination treatments by introducing
short-hairpin RNA (shRNA) for Bim to downregulate its expression. Figure 22 shows
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consistent expressions of cleaved-PARP in both combination treatments even after BIM
was down-regulated. While pro-apoptotic protein Noxa is known for its high affinity to prosurvival protein MCL-1, BIM is known to interact with MCL-1, BCL-2, and BCL-XL. We
speculate that BIM may be going through caspase- and/or proteasome-mediated
degradation as a consequence of apoptosis. This may be due to strong induction of Noxa in
both combination treatments. When Noxa is induced and further bound to MCL-1 to inhibit
its pro-survival activity, BIM may be losing its competition against Noxa to interact with
MCL-1 and just simply undergoes the degradation process. Results obtained from Western
blot analysis were also further confirmed through FACS analysis shown in figure 23.
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